Veru Inc. Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation Strategy

Reuters10-17

<a href="https://laohu8.com/S/VERU">Veru Inc.</a> Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation <a href="https://laohu8.com/S/MSTR">Strategy</a>

Veru Inc. has provided an overview of its cardiometabolic drug development pipeline, focusing on treatments for obesity and atherosclerosis. The company is advancing a combination of enobosarm, an oral selective androgen receptor modulator (SARM), with a GLP-1 receptor agonist for weight loss maintenance in older patients. This combination aims to preserve muscle mass and enhance fat loss, addressing the significant lean mass reduction associated with current GLP-1 receptor agonist therapies. Phase 2 studies have shown positive results, with further clinical trials planned. Additionally, Veru is developing sabizabulin, an oral microtubule disruptor, for the treatment of inflammation in stable coronary artery disease. The scientific advisory board includes leading experts in endocrinology, metabolism, and cardiology. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2576477984?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-17 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576477984","market":"us","top_or_hot":-1,"title":"Veru Inc. Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation Strategy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VERU\">Veru Inc.</a> Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation <a href=\"https://laohu8.com/S/MSTR\">Strategy</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Veru Inc. has provided an overview of its cardiometabolic drug development pipeline, focusing on treatments for obesity and atherosclerosis. The company is advancing a combination of enobosarm, an oral selective androgen receptor modulator (SARM), with a GLP-1 receptor agonist for weight loss maintenance in older patients. This combination aims to preserve muscle mass and enhance fat loss, addressing the significant lean mass reduction associated with current GLP-1 receptor agonist therapies. Phase 2 studies have shown positive results, with further clinical trials planned. Additionally, Veru is developing sabizabulin, an oral microtubule disruptor, for the treatment of inflammation in stable coronary artery disease. The scientific advisory board includes leading experts in endocrinology, metabolism, and cardiology. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Veru Inc. Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation Strategy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVeru Inc. Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation Strategy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-17 05:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VERU\">Veru Inc.</a> Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation <a href=\"https://laohu8.com/S/MSTR\">Strategy</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Veru Inc. has provided an overview of its cardiometabolic drug development pipeline, focusing on treatments for obesity and atherosclerosis. The company is advancing a combination of enobosarm, an oral selective androgen receptor modulator (SARM), with a GLP-1 receptor agonist for weight loss maintenance in older patients. This combination aims to preserve muscle mass and enhance fat loss, addressing the significant lean mass reduction associated with current GLP-1 receptor agonist therapies. Phase 2 studies have shown positive results, with further clinical trials planned. Additionally, Veru is developing sabizabulin, an oral microtubule disruptor, for the treatment of inflammation in stable coronary artery disease. The scientific advisory board includes leading experts in endocrinology, metabolism, and cardiology. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4183","symbol_name":"个人用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251016:nNDL8TXRX:1","article_id":"2576477984","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576477984","pubTimestamp":1760650862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Veru Inc. has provided an overview of its cardiometabolic drug development pipeline, focusing on treatments for obesity and atherosclerosis. The company is advancing a combination of enobosarm, an oral selective androgen receptor modulator , with a GLP-1 receptor agonist for weight loss maintenance in older patients. This combination aims to preserve muscle mass and enhance fat loss, addressing the significant lean mass reduction associated with current GLP-1 receptor agonist therapies. Phase 2 studies have shown positive results, with further clinical trials planned. Additionally, Veru is developing sabizabulin, an oral microtubule disruptor, for the treatment of inflammation in stable coronary artery disease. The scientific advisory board includes leading experts in endocrinology, metabolism, and cardiology. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4183":"个人用品","BK4557":"大麻股","VERU":"Veru Inc.","BK4007":"制药","BK4584":"避孕概念"},"translate_title":"Veru Inc.推出新演示文稿，重点介绍肥胖药物管道和肌肉保护策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERU":0.9},"content_text":"Veru Inc. Unveils New Presentation Highlighting Obesity Drug Pipeline and Muscle Preservation Strategy\n\n\n        Veru Inc. has provided an overview of its cardiometabolic drug development pipeline, focusing on treatments for obesity and atherosclerosis. The company is advancing a combination of enobosarm, an oral selective androgen receptor modulator (SARM), with a GLP-1 receptor agonist for weight loss maintenance in older patients. This combination aims to preserve muscle mass and enhance fat loss, addressing the significant lean mass reduction associated with current GLP-1 receptor agonist therapies. Phase 2 studies have shown positive results, with further clinical trials planned. Additionally, Veru is developing sabizabulin, an oral microtubule disruptor, for the treatment of inflammation in stable coronary artery disease. The scientific advisory board includes leading experts in endocrinology, metabolism, and cardiology. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veru Inc. published the original content used to generate this news brief on October 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2576477984","isCrawlerRequest":true}